A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma
NCT ID: NCT05343377
Last Updated: 2022-04-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
72 participants
INTERVENTIONAL
2022-06-01
2028-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
NCT06089941
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
NCT05821192
A Single-cell Transcriptome Study in Patients With Non-Hodgkin's Lymphoma
NCT04434833
Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
NCT07162012
A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission
NCT05874778
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
circulate free methylated EBV DNA predicts PFS rate in ENKTCL
circulate free methylated EBV DNA
Accuracy of circulating free methylated EBV DNA in predicting 2-year PFS
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
circulate free methylated EBV DNA
Accuracy of circulating free methylated EBV DNA in predicting 2-year PFS
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sign written informed consent and be able to comply with the visits and related procedures specified in the protocol
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhenjiang First People's Hospital
OTHER
Changzhou First People's Hospital
UNKNOWN
Changzhou Second People's Hospital
UNKNOWN
Wuxi People's Hospital
OTHER
Second Affiliated Hospital of Soochow University
OTHER
The First Affiliated Hospital of Nantong University
UNKNOWN
Huaian first people's hospital
UNKNOWN
Yancheng First People's Hospital
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Nanjing Medical University
Nanjing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-GL1-AF02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.